Michael B Wheeler

Michael B Wheeler, PhD

The Wheeler lab employs a systems-physiology approach to research using innovative high-throughput techniques, incorporating mass-spectrometry and the membrane yeast two-hybrid system. This approach enables the Wheeler lab to perform powerful screens capable of revealing novel targets at an unprecedented rate. These screens are complemented by primary research that utilizes primary cells, cell lines and mouse models to ensure the results are biologically relevant. The lab focuses on two exciting research streams:
  • Assessing the Diabetic Effect on Metabolism in Humans using Metabolomics
    The Wheeler lab is exploring the use of metabolomics as a tool to directly assess the diabetic effect on metabolism in humans. Metabolomics is a recent technological advance that characterizes metabolites, the final compounds of chemical reactions and those most relevant to metabolic diseases such as diabetes. This approach forms the basis of multiple predictive- and causative-oriented investigations in our lab for gestational and type 2 diabetes.
  • Identification of GLP-1R Interactors as Potential Drug Targets for Type II Diabetes
    Using high-throughput technologies, incorporating mass spectrometry and MYTH screening, the Wheeler lab has identified a large number proteins that interact with the glucagon like peptide-1 receptor (GLP-1R) in a variety of tissues, including mouse and human islets. Following the identification and verification of GLP-1R interactors, members of the Wheeler lab characterize potential functional changes to glucose stimulated insulin secretion, GLP-1 binding, and proliferation and survival. Ultimately, candidate GLP-1R interactors that elicit significant functional changes are selected for further mechanistic studies. Identifying and characterizing GLP-1R interactors may reveal potential drug targets that can be utilized to improve the lives of those living with type 2 diabetes.
Cell Tissue Res. 2018 Jan 09;:
Milner DJ, Bionaz M, Monaco E, Cameron JA, Wheeler MB
EBioMedicine. 2017 Dec 19;:
Prentice KJ, Wendell SG, Liu Y, Eversley JA, Salvatore SR, Mohan H, Brandt SL, Adams AC, Serena Wang X, Wei D, FitzGerald GA, Durham TB, Hammond CD, Sloop KW, Skarke C, Schopfer FJ, Wheeler MB
Theriogenology. 2017 Nov 04;107:95-103
Cadenas J, Maside C, Ferreira ACA, Vieira LA, Leiva-Revilla J, Paes VM, Alves BG, Brandão FZ, Rodrigues APR, Wheeler MB, Figueiredo JR
Nat Commun. 2017 Aug 08;8(1):210
Nguyen TH, Kandel ME, Rubessa M, Wheeler MB, Popescu G
Diabetologia. 2017 Jul 20;:
Ivovic A, Oprescu AI, Koulajian K, Mori Y, Eversley JA, Zhang L, Nino-Fong R, Lewis GF, Donath MY, Karin M, Wheeler MB, Ehses J, Volchuk A, Chan CB, Giacca A
Mol Metab. 2017 Jul;6(7):760-769
Seshadri N, Jonasson ME, Hunt KL, Xiang B, Cooper S, Wheeler MB, Dolinsky VW, Doucette CA
Homeopathy. 2017 May;106(2):87-92
de Lima LF, Rubessa M, Rocha RMP, Winters R, Milner DJ, Campello CC, Figueiredo JR, Wheeler MB
Mol Hum Reprod. 2017 Mar 29;:269
Wheeler MB, Rubessa M
Anim Biotechnol. 2017 Mar 07;:1-13
Rubessa M, Polkoff K, Bionaz M, Monaco E, Milner DJ, Holllister SJ, Goldwasser MS, Wheeler MB
J Med Chem. 2017 Feb 07;:
Nagy E, Liu Y, Prentice KJ, Sloop KW, Sanders PE, Batchuluun B, Hammond CD, Wheeler MB, Durham TB



Professor, University of Toronto, Department of Physiology, Faculty of Medicine